It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics ...

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an ...

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically ...

A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance ...

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell ...

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to ...

The company made the announcement after a new round of research results bolstered the case for the experimental medicine, ...

Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, ...

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an ...

Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 ...

Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for ...